Abstrait

Anti-hyperglycemic and anti-hyperlipidemic activities of Radix Astragali and Panax notoginseng extract in human participants: A randomized, double-blind, crossover clinical trial.

Shih-Chien Huang1, Ching-Pin Lin2, Jing-Yi Hu1, and You-Cheng Shen3*

To the best of our knowledge, there is no clinical trial conducted with a standardized Astragalus and notoginseng extract (ANS) in human subjects. The goal of the current study is to investigate the effect of ANS on hyperglycemia and dyslipidemia regulation and its mechanism of action in pre-diabetic with hyperlipidemia human subjects. This randomized, double-blinded crossover trial was conducted in participants aged >20 years, with fasting blood glucose levels 100–125 mg/dL, glycosylated hemoglobin (HbA1C) 5.8–6.4%, and cholesterol 200–249 mg/dL. Eligible participants were asked to take five ANS or placebo capsules daily for 6 weeks. Changes in blood glucose and lipids levels were measured every three weeks. Fasting blood glucose and lipids, oralglucose- tolerance-test, small dense low-density lipoprotein-cholesterol (sdLDL-C), high-density lipoprotein-cholesterol (HDL-C), adiponectin, HbA1C, and adenosine monophosphate-activated protease kinase (AMPK) were measured. Renal and hepatic functions were analyzed for any adverse effects. After 6 weeks of ANS supplementation, fasting blood glucose and glucose area under the curve (AUC) were significantly decreased by 10.1% and 12.69% (p<0.05), respectively. Triglycerides and sdLDL-C were significantly decreased by 31.06% and 19.96% (p<0.05), respectively, in the ANS group than in the placebo group. HDL-C, adiponectin, and AMPK were significantly increased by 11.78%, 22.07%, and 12.72% (p<0.05), respectively in the ANS group than in the placebo group. The above results indicate that oral supplementation with ANS reduces hyperglycemia and dyslipidemia without adverse events.